Your browser doesn't support javascript.
loading
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.
Weingold, Robert; Zinman, Bernard; Mattheus, Michaela; Ofstad, Anne Pernille; Steubl, Dominik; Wanner, Christoph; Inzucchi, Silvio E.
Affiliation
  • Weingold R; Yale School of Medicine, New Haven, CT, USA.
  • Zinman B; Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
  • Mattheus M; Boehringer Ingelheim International GmbH & Co. KG, Ingelheim, Germany.
  • Ofstad AP; Boehringer Ingelheim Norway KS, Asker, Norway; Oslo Diabetes Research Center, Oslo, Norway.
  • Steubl D; Boehringer Ingelheim International GmbH & Co. KG, Ingelheim, Germany; Department of Nephrology, Hospital rechts der Isar, Technical University Munich, Munich, Germany.
  • Wanner C; Würzburg University Clinic, Würzburg, Germany.
  • Inzucchi SE; Yale School of Medicine, New Haven, CT, USA. Electronic address: silvio.inzucchi@yale.edu.
J Diabetes Complications ; 37(11): 108628, 2023 11.
Article in En | MEDLINE | ID: mdl-37852075
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Insufficiency, Chronic / Sodium-Glucose Transporter 2 Inhibitors Limits: Humans Language: En Journal: J Diabetes Complications Journal subject: ENDOCRINOLOGIA Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Insufficiency, Chronic / Sodium-Glucose Transporter 2 Inhibitors Limits: Humans Language: En Journal: J Diabetes Complications Journal subject: ENDOCRINOLOGIA Year: 2023 Document type: Article Affiliation country: Country of publication: